Boston Scientific Corp (BSX) concluded trading on Wednesday at a closing price of $100.31, with 8.13 million shares of worth about $815.62 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 28.16% during that period and on January 22, 2025 the price saw a loss of about -0.59%. Currently the company’s common shares owned by public are about 1.47B shares, out of which, 1.47B shares are available for trading.
Stock saw a price change of 4.87% in past 5 days and over the past one month there was a price change of 13.95%. Year-to-date (YTD), BSX shares are showing a performance of 12.30% which increased to 64.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $59.85 but also hit the highest price of $101.14 during that period. The average intraday trading volume for Boston Scientific Corp shares is 5.78 million. The stock is currently trading 7.26% above its 20-day simple moving average (SMA20), while that difference is up 10.01% for SMA50 and it goes to 23.40% higher than SMA200.
Boston Scientific Corp (NYSE: BSX) currently have 1.47B outstanding shares and institutions hold larger chunk of about 91.07% of that.
The stock has a current market capitalization of $147.84B and its 3Y-monthly beta is at 0.81. PE ratio of stock for trailing 12 months is 82.97, while it has posted earnings per share of $1.21 in the same period. Its PEG reads 5.84 and has Quick Ratio of 1.02 while making debt-to-equity ratio of 0.54. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BSX, volatility over the week remained 1.57% while standing at 1.68% over the month.
Analysts are in expectations that Boston Scientific Corp (BSX) stock would likely to be making an EPS of 0.66 in the current quarter, while forecast for next quarter EPS is 0.64 and it is 2.81 for next year. For the current quarter EPS, analysts have given the company a lowest target 0.64 which is 0.68 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 0.55 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 20.27% while it is estimated to increase by 13.99% in next year. EPS is likely to grow at an annualized rate of 14.20% for next 5-years, compared to annual growth of -2.05% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Deutsche Bank on January 10, 2025 offering a Buy rating for the stock and assigned a target price of $108 to it. On May 30, 2024, Goldman Initiated their recommendations, while on February 01, 2024, Mizuho Upgrade their ratings for the stock with a price target of $80. Stock get an Outperform rating from Robert W. Baird on July 19, 2023.
